<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2015-03287-282-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Clinical field studies for point-of-care diagnostics using miniature microscopy scanners</narrative>
   <narrative xml:lang="SV">Kliniska f&#xE4;ltstudier f&#xF6;r patientn&#xE4;ra diagnostik med minimikroskop</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">V&#xE5;r forskargrupp har utvecklat en miniatyrmikroskop-skanner som b&#xE5;de tar bilder av provet, s&#xE4;nder dem till en centraldator och kan ta emot resultat g&#xE4;llande diagnostiska fynd. Snabb &#xF6;verf&#xF6;ring av data via mobila n&#xE4;tverk m&#xF6;jligg&#xF6;r bild&#xF6;verf&#xF6;ring fr&#xE5;n det mobila miniatyrmikroskopet till en centraldator som kan utf&#xF6;ra sofistikerad bildanalys av provet eller analyseras visuellt av t.ex. en laboratorieanalytiker i en patientn&#xE4;ra situation. V&#xE5;r nyligen verkst&#xE4;llda kliniska utv&#xE4;rderingsstudie visade att metoden &#xE4;r genomf&#xF6;rbar och nu &#xE4;mnar vi utf&#xF6;ra kliniska f&#xE4;ltstudier med det nya diagnostiska systemet i tv&#xE5; patientgrupper i Tanzania, 1: som en diagnostisk metod f&#xF6;r att uppt&#xE4;cka malaria i blodprov hos feberpatienter vid en lokal v&#xE5;rdscentral och 2: som en diagnostisk- och monitoreringsmetod f&#xF6;r jord-&#xF6;verf&#xF6;rbara tarmparasiter i avf&#xF6;ringsprov samt schistosomiasis i avf&#xF6;rings-och urinprov hos skolbarn inom en infektionsbevaknings-unders&#xF6;kning. B&#xE5;de malaria och jord-&#xF6;verf&#xF6;rbara maskar har en betydande negativ p&#xE5;verkan p&#xE5; individens h&#xE4;lsa i resursfattiga omr&#xE5;den.   Bilderna tagna av patientproverna med minatyrmikroskopet &#xF6;verf&#xF6;rs till en centraldator d&#xE4;r malariaparasiter fr&#xE5;n blodutsryk och mask&#xE4;gg i avf&#xF6;rings- och urinproven detekteras med moderna bildanalysmetoder och resultatet skickas tillbaka till personen som handhar diagnostiken vid v&#xE5;rdscentralen. Denna studie f&#xF6;r patientn&#xE4;ra diagnostik kommer att utf&#xF6;ras p&#xE5; landsbygden i Tanzania i samarbete med Muhimbili universitetet. Inom studien kommer vi att j&#xE4;mf&#xF6;ra det nya diagnostiska systemet med traditionell mikroskopi bl.a. g&#xE4;llande diagnostisk tr&#xE4;ffs&#xE4;kerhet, anv&#xE4;ndarv&#xE4;nlighet, och tolkning av resultaten. Detta nya m&#xE5;ngsidiga diagnostiska system kommer att f&#xF6;ra diagnostiken fr&#xE5;n laboratoriet till den patientn&#xE4;ra behandlingssituationen. Miniatyrmikroskopet &#xE4;r konstruerat av komponenter framtagna av mobiltelefonindustrin, anv&#xE4;nder sig av mobila n&#xE4;tverk och till&#xE5;ter analys av bilder i digitala moln-milj&#xF6;er. Metoden medverkar till att bek&#xE4;mpa infektionssjukdomar och &#xF6;kar tillg&#xE5;ngen till diagnostik, minskar tiden till diagnos och behandling samt m&#xF6;jligg&#xF6;r en resursomf&#xF6;rdelning inom h&#xE4;lsov&#xE5;rden i resursfattiga omr&#xE5;den.</narrative>
   <narrative xml:lang="EN">We have developed a low-cost miniaturized microscopy scanner that digitizes patient samples at high magnification and transfers the generated virtual slides over mobile networks. Our central server receives the virtual slides and allows the biological samples to be remotely analyzed by automated computer vision or visually assessed by a human observer. A proof-of-concept study supported by the Swedish Research Council has been conducted in 2014-2015 and shown the method to be feasible.  We now plan to implement the novel multipurpose diagnostic platform in two settings in Tanzania: 1) As a diagnostic method for detection of malaria in blood samples obtained from patients presenting with fever at the primary health care level and 2) as a diagnostic and monitoring method for detection of soil-transmitted helminthes and schistosomiasis in stool and urine obtained from schoolchildren within a transmission surveillance survey. Captured digital images of the specimens are transferred to the central server to detect malaria parasites in blood smears, and helminth eggs in stool and urine, and to return the results to the technician in the field.  The point-of-care study will be carried out in the Bagamoyo District and the transmission surveillance study in the Masasi/Muheza District in Tanzania in collaboration with Muhimbili University of Health and Allied Sciences (MUHAS). The study will include a comparison with conventional microscopy with regard to diagnostic accuracy (sensitivity, specificity, positive and negative predictive value), an evaluation of usability, interpretability and assessment of time to achieve diagnosis. The project advances the field by bringing a powerful, multiplexed diagnostic tool from the laboratory to the point-of-care. The instruments are constructed out of components of mobile phones, make use of the expanding mobile networks and allow remote image processing in a highly scalable cloud computing environment. Previous mobile microscopy projects have been limited with regard to the sample area that can be captured, whereas the technology to be tested in the current project can digitally scan an entire microscopy slide. The method will aid in the combat of infectious diseases at the point-of-care level of health care and has the potential to improve access to diagnostics, enable task-shifting and shorten the time to diagnosis.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">University, college or other teaching institution, research institute or think-tank</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2016-01-01" type="1"></activity-date>
  <activity-date iso-date="2016-01-01" type="2"></activity-date>
  <activity-date iso-date="2019-12-31" type="3"></activity-date>
  <activity-date iso-date="2019-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="TZ" percentage="100">
   <narrative xml:lang="EN">Tanzania, United Republic of</narrative>
  </recipient-country>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">126804.1839537194</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">126945.1269451269</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">124850.409647427</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-11-27"></transaction-date>
   <value currency="USD" value-date="2015-11-27">386153.0613455447</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">126804.1839537194</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-28"></transaction-date>
   <value currency="USD" value-date="2017-01-28">126945.1269451269</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-28"></transaction-date>
   <value currency="USD" value-date="2018-01-28">124850.409647427</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
